| Date | Title | | | 08/25/10 | Cephalon Announces Chairman and CEO to Take Medical Leave of Absence| FRAZER, Pa., Aug 25, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc., (Nasdaq: CEPH) today announced Frank Baldino, Jr., Ph.D., the company's Chairman and Chief Executive Officer, will take a temporary medical leave of absence, effective immediately. During Dr. Baldino's absence, J. Kevin Buchi, the company's Chief Operating Officer, will assume Dr. Baldino's responsibilities. Prior to assuming the newly-created role of Chief Operating Officer earlier this year, Mr. Buchi served as the company's... |
|  | | 07/27/10 | Cephalon Reports Record Sales and Earnings in Second Quarter 2010|
Quarterly Sales of $712 Million Increased 32 Percent
Quarterly Basic Adjusted EPS of $2.20 Increased 41 Percent
Ex-US Sales Exceed 25 Percent of Worldwide Sales for the First Time
FRAZER, Pa., July 27, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2010 sales of $712.4 million, a 32 percent increase compared to sales of $539.0 million for the second quarter 2009. Basic income per common share for the quarter was $1.18. Excluding amortizat... |
| | | 07/21/10 | Cephalon Expects Second Quarter 2010 Results to Exceed Previously Issued Guidance| FRAZER, Pa., July 21, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that, based on preliminary financial results, it expects sales and basic adjusted income per common share for the second quarter 2010 to exceed its previously issued guidance driven largely by strong product sales. The company now anticipates that sales for the second quarter 2010 will be between $705-715 million, up from the previous sales guidance of $645-670 million, resulting in basic adjusted... |
| | | 06/24/10 | Cephalon Second Quarter 2010 Earnings Conference Call Tuesday, July 27, 2010 at 5:00 p.m. EDT| FRAZER, Pa., June 24, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering second quarter 2010 results for 5:00 p.m. EDT on Tuesday, July 27, 2010.
July 27, 2010
Schedule
4:10 p.m. EDT
Q2 2010 results will be distributed by PRNewswire
4:50 p.m. EDT
To participate in the conference call, dial 913-312-1497 and refer to Conference Code Number 3249552
5:00 p.m. EDT
... |
| | | 06/23/10 | Cephalon Partners with American Chronic Pain Association and the American Pharmacists Association to Expand National Initiative On the Safe and Appropriate Use of Prescription Medicines| Patients to Receive Educational Information at Pharmacies and Online
FRAZER, Pa., June 23, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) today announced that it has partnered with the American Chronic Pain Association (ACPA) and the American Pharmacists Association (APhA) to broaden the company's When Good Medicines Become Bad Drugs(SM) program. This national education campaign provides patients, caregivers and the public with information about the abuse of prescription medicati... |
| | | 06/02/10 | Cephalon Provides Clinical Update on Phase II Study of NUVIGIL as an Adjunctive Therapy in Adults with Schizophrenia| FRAZER, Pa., June 2, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL(R) (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal. The analysis of the data showed that treatment with armodafinil did not lessen the severity of the negative symptoms of schizophre... |
| | | 05/04/10 | Cephalon off to Record Start in 2010|
Quarterly Sales of $577 Million Increased 12 Percent
Quarterly Adjusted EPS of $1.92 Increased 31 Percent
Quarterly Cash from Operations totaled $234 Million
FRAZER, Pa., May 4, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) today reported first quarter 2010 sales of $576.7 million, a 12 percent increase compared to sales of $514.4 million for the first quarter 2009. Basic income per common share for the quarter was $1.47. Excluding amortization expense and certain othe... |
| | | 04/09/10 | Cephalon Completes Acquisition of Swiss Pharmaceutical Company Mepha|
Acquisition Diversifies Global Pharmaceutical Business and Expands Presence in Western and Central Europe, Africa, and Middle East Territories
FRAZER, Pa., AESCH, Switzerland and MAISONS-ALFORT, France, April 9, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase... |
| | | 04/05/10 | Cephalon Completes Acquisition of Ception Therapeutics|
Acquisition Adds Biologics Asset for Advancement to Phase Three Development
FRAZER, Pa., April 5, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.
Cephalon Chairman and CEO Frank Baldino Jr., Ph.D., said "We are fortunate to have the opportunity to advance CINQUIL(TM) (reslizumab) into Pha... |
| | | 03/31/10 | Cephalon First Quarter 2010 Earnings Conference Call Tuesday, May 4, 2010 at 5:00 p.m. EDT| FRAZER, Pa., March 31, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering first quarter 2010 results for 5:00 p.m. EDT on Tuesday, May 4, 2010.
May 4, 2010 Schedule
4:10 p.m. EDT
Q1 2010 results will be distributed by PRNewswire
4:50 p.m. EDT
To participate in the conference call, dial 913-981-4915 and refer to Conference Code Number 3364849
5:00 p.m. EDT ... |
| | | 03/29/10 | Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder| FRAZER, Pa., March 29, 2010 /PRNewswire via COMTEX/ --Cephalon, Inc. (Nasdaq: CEPH) today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL(R) (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.
As the first company to study a treatment option to improve wakefulness associated with je... |
| | | 02/23/10 | Cephalon Exercises its Option to Acquire Ception Therapeutics| Ception Delivers Positive Results from a Phase II Study of CINQUIL in Adult Eosinophilic Asthma
FRAZER, Pa. and MALVERN, Pa., Feb 23, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma. A Phase II clinical trial of Ception's lead compound, CINQUIL(TM) (reslizumab), in 106 patients demonstrated improved asth... |
| | | 02/11/10 | Cephalon Reports Record Sales and Adjusted Net Income for 2009| --Sales Exceed $2 Billion, Increasing for Tenth Year in a Row --2010 Guidance Increased --Cash From Operations Totals $681 MillionFRAZER, Pa., Feb 11, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2009 net sales of $2.152 billion, an 11 percent increase compared to net sales of $1.943 billion for 2008. Basic income per common share for the year was $4.74. Excluding amortization expense and certain other items, adjusted net income for full year 2009 was $469 mill... |
| | | 02/01/10 | Cephalon, Inc. Announces Agreement to Acquire Mepha AG| Expands Range of Products and Reach in Europe, Africa, and the Middle East
Transaction Expected to be Immediately Accretive to Adjusted Earnings Per Share
FRAZER, Pa., AESCH, Switzerland, and MAISONS-ALFORT, France, Feb 01, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company. Mepha has specific expertise in innovative dosage formul... |
| | | 01/28/10 | Cephalon Announces Executive Leadership Changes| FRAZER, Pa., Jan 28, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced the promotion of three executives, Kevin Buchi, Wilco Groenhuysen and Alain Aragues.
Kevin Buchi is promoted to a new position as Chief Operating Officer with responsibility for Worldwide Pharmaceutical Operations, Worldwide Technical Operations, Investor Relations and Business Development. Mr. Buchi joined Cephalon in 1991 and became Chief Financial Officer (CFO) in 1996.
"During his 18 years... |
| | | 01/08/10 | Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position| FRAZER, Pa., Jan 08, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that effective February 5, 2010, Robert P. Roche, Jr., Executive Vice President of Worldwide Pharmaceutical Operations, will resign his position with the company to pursue other longstanding interests. During his tenure, Mr. Roche established and grew the Cephalon sales and marketing organization into a global business that exceeded $2 billion in annual sales revenue. The company will announce pla... |
| | | 01/08/10 | Cephalon Fourth Quarter & Full Year 2009 Earnings Conference Call Thursday, February 11, 2010 at 5:00 p.m. EST| FRAZER, Pa., Jan 08, 2010 /PRNewswire via COMTEX/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering fourth quarter and full year 2009 results for 5:00 p.m. EST on Thursday, February 11, 2010.
February 11, 2010 Schedule
4:10 p.m. EST
Q4 & FY 2009 results will be distributed by PRNewswire
4:50 p.m. EST
To participate in the conference call, dial 913-312-0705 and refer to Conference Code Number 2954672
5:00 p.m. EST
Conferenc... |
| |
|
Print Page | 
Email Page | 
RSS Feeds | 
Financial Tear Sheet